PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010 2011 2012 2013 2014
2009 Achievements
This activity supported the recently concluded HHS/CDC/BOTUSA clinical trial on IPT. The findings were presented at a special session at the Annual Global Conference of the International Union Against Tuberculosis and Lung Disease (IUATLD) held in Cancun, Mexico.
2010 Plans
This activity will require $500,000 to fund a public health evaluation (PHE) by HHS/CDC/BOTUSA and the University of Botswana School of Medicine (UBSOM) to evaluate enhanced tuberculosis case-management to reduce mortality and morbidity among persons with advanced HIV infection presenting for HIV care in sub-Saharan African countries. In many African countries, patients with advanced HIV infection who are assessed for antiretroviral therapy (ART) and those in the first months of ART have a high risk of dying. Thereafter, their mortality is similar to that of patients in other parts of the world. The reasons for this higher mortality are not clear, but it is hypothesized that it is due to tuberculosis (TB), which is one of the leading cause of death among persons living with HIV (PLWHA) in Africa. In Botswana, which has one of the highest rates of TB in the world at 600 cases/100,000 over 80% of incident TB cases are also HIV positive. This study will assess whether enhanced TB diagnosis leading to earlier initiation of TB therapy will reduce deaths and hospitalization in this population.
Objectives of PHE
To evaluate the efficacy of enhanced TB case-finding to reduce six-month mortality and morbidity among patients with advanced HIV disease presenting for care at HIV clinics. The intervention consists of a TB case manager to assure comprehensive TB screening and enhanced laboratory testing (fluorescence microscopy, liquid-media mycobacterial culture and molecular line-probe assay).
Site Specific Details
Botswana will contribute 10 sites, randomized to receive standard of care or TB case manager to the study and represent the 5th country to join the multi-country protocol and the only southern African country. The study will be implemented and coordinated by the TB-HIV Research Division of BOTUSA (PI - Dr. James Shepherd) in collaboration with the Department of Medicine, University of Botswana School of Medicine (Co PI- Dr. Sandro Vento). The School of Medicine is brand new and has limited capacity for operational research at the current time so that the personnel, study management, data management and other study functions will be carried out by the TB-HIV Research Division of BOTUSA with UBSOM faculty, scientists and students as partners to build their capacity to develop operational research programs in the future.
Operations Costs
In order to implement the aforementioned activities, some funding may be utilized for operational costs.
10.C.TB08: HHS/CDC/Botusa TB section support - 500,000.00
2010 Plans.
This activity will require $250,000 to fund a public health evaluation (PHE) by HHS/CDC/BOTUSA and the University of Botswana School of Medicine (UBSOM) to evaluate enhanced tuberculosis case-management to reduce mortality and morbidity among persons with advanced HIV infection presenting for HIV care in sub-Saharan African countries. In many African countries, patients with advanced HIV infection who are assessed for antiretroviral therapy (ART) and those in the first months of ART have a high risk of dying. Thereafter, their mortality is similar to that of patients in other parts of the world. The reasons for this higher mortality are not clear, but it is hypothesized that it is due to tuberculosis (TB), which is one of the leading cause of death among persons living with HIV (PLWHA) in Africa. In Botswana, which has one of the highest rates of TB in the world at 600 cases/100,000 over 80% of incident TB cases are also HIV positive. This study will assess whether enhanced TB diagnosis leading to earlier initiation of TB therapy will reduce deaths and hospitalization in this population.
To evaluate the efficacy of enhanced TB case-finding to reduce six-month mortality and
morbidity among patients with advanced HIV disease presenting for care at HIV clinics.
The intervention consists of a TB case manager to assure comprehensive TB screening
and enhanced laboratory testing (fluorescence microscopy, liquid-media mycobacterial
culture and molecular line-probe assay).
10.C.TB90: Technical expertise & support PC/TB - 150,000.00
FY10 funds will be requested to support the salary of one FSN and one contractor, and travel costs of the FSN for site visits and attendance at regional and international meetings. Funds will also be requested to support the printing of national TB/HIV guidelines and IEC materials, to support the maintenance and development of the electronic TB register (ETR.Net), to pilot mobile telephony technology for TB data transmission, and to procure one laptop and a printer for use by TB/HIV program officers. Contingency funds will be requested for anticipated requests for emergency IC measures (e.g., ultraviolet light fittings, fans, respirators) in the MDR-TB sites and in selected Infectious Disease Care Clinics (IDCCs).
FY10 funds will be requested to provide TA from CDC Atlanta for the following activities: to assess treatment outcomes among TB patients with INH mono-resistance; a pilot project to intensify TB case finding in health facilities in Francistown; an intervention project on TB infection control in the national prison network; and a project to assess transmission in outpatient care settings that serve persons with HIV-infection and evaluate measures to reduce TB transmission in these outpatient care settings
10.C.TB91: Technical expertise & support PC/TB - 262,649.00
